Method of inducing bone formation

• US 20030031660A1
• Filed: 06/07/2002
• Published: 02/13/2003
• Est. Priority Date: 09/02/1997
• Status: Abandoned Application

• Current Assignee: Insight Strategy & Marketing Ltd.
• Original Assignee: Insight Strategy & Marketing Ltd.
• Inventors: Yacoby-Zeevi, Oron
• Application Number:
  US10/163,993
• Publication Number:
  US 20030031660A1
• Time in Patent Office: Days
• US Class Current: 424/94.61
• CPC Class Codes: A01K 67/0271 Chimeric vertebrates, e.g. comprising exogenous cells
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/486 Elastase (3.4.21.36 or 3.4.21.37)
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61K 38/51 Lyases (4)
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 9/2402 hydrolysing O- and S- glycosyl compounds (3.2.1)
• CPC Class Codes: C12Y 302/01128 Glycyrrhizinate beta-glucuronidase (3.2.1.128), i.e. GL beta-D-glucoronidase
• CPC Class Codes: C12Y 302/01166 Heparanase (3.2.1.166)
• CPC Class Codes: G06F 18/24323 Tree-organised classifiers

Abstract

A method of inducing bone formation in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of heparanase. A pharmaceutical composition for inducing bone formation in a subject in need thereof, the pharmaceutical composition comprises, as an active ingredient, a therapeutically effective amount of heparanase, and a pharmaceutically acceptable carrier.

Claims

1. A method of inducing bone formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of heparanase.

2. The method of claim 1, wherein said heparanase is a proheparanase.

3. The method of claim 1, wherein said heparanase is a processed heparanase.

4. The method of claim 1, wherein the subject has a medical condition characterized by bone loss, reduced bone mass or bone fracture.

5. The method of claim 1, wherein the subject has osteogenesis imperfecta.

6. The method of claim 1, wherein the subject has osteoporosis.

7. The method of claim 1, wherein the subject has a periodontal disease or a mucopolysaccharidoses associated bone defect.

8. The method of claim 1, wherein the subject has a bone void.

9. The method of claim 1, wherein administering is via intrabone injection.

10. A pharmaceutical composition for inducing bone formation in a subject in need thereof, the pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of heparanase, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein said heparanase is a proheparanase.

12. The pharmaceutical composition of claim 10, wherein said heparanase is a processed heparanase.

13. The pharmaceutical composition of claim 10, contained in a container and identified in print for use in a subject having a medical condition characterized by bone loss, reduced bone mass or bone fracture.

14. The pharmaceutical composition of claim 10, contained in a container and identified in print for use in a subject having osteogenesis imperfecta.

15. The pharmaceutical composition of claim 10, contained in a container and identified in print for use in a subject having osteoporosis.

16. The pharmaceutical composition of claim 10, contained in a container and identified in print for use in a subject having a periodontal disease or a mucopolysaccharidoses associated bone defect.

17. The pharmaceutical composition of claim 10, contained in a container and identified in print for use in a subject having a bone void.

18. The pharmaceutical composition of claim 10, formulated for administration via intrabone injection.